Psoriasis 3, susceptibility to

Summary

Psoriasis 3, susceptibility to (MONDO:0011084) is a disease. A subtype of psoriasis, susceptibility to — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	psoriasis 3, susceptibility to
Mondo ID	MONDO:0011084
OMIM	601454
DOID	DOID:0111283
UMLS	C1832345
MedGen	316964
Is cancer (heuristic)	no

Also known as: psoriasis 3, susceptibility to · psoriasis susceptibility 3 · PSORS3

Disease family

This is a subtype of psoriasis, susceptibility to. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease susceptibility › inherited disease susceptibility › psoriasis, susceptibility to › psoriasis 3, susceptibility to

Related subtypes (12): psoriasis 1, susceptibility to, psoriasis 4, susceptibility to, psoriasis 5, susceptibility to, psoriasis 6, susceptibility to, psoriasis 7, susceptibility to, psoriasis 9, susceptibility to, psoriasis 8, susceptibility to, psoriasis 10, susceptibility to, psoriasis 11, susceptibility to, psoriasis 12, susceptibility to, psoriasis 13, susceptibility to, psoriasis 15, pustular, susceptibility to

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.